Update on rifampin, rifabutin, and rifapentine drug interactions

被引:129
作者
Baciewicz, Anne M. [1 ]
Chrisman, Cary R. [2 ]
Finch, Christopher K. [3 ]
Self, Timothy H. [3 ]
机构
[1] VA Puget Sound Hlth Care Ctr, Seattle, WA USA
[2] Methodist Med Ctr Oak Ridge, Oak Ridge, TN USA
[3] Univ Tennessee, Methodist Univ Hosp, Hlth Sci Ctr, Memphis, TN 38163 USA
关键词
Drug interactions; Rifabutin; Rifampin; Rifapentine; PLASMA-CONCENTRATIONS; TRANSPORTER INHIBITION; PLATELET-AGGREGATION; HEALTHY-VOLUNTEERS; ENZYME-INDUCTION; SINGLE-BLIND; PHARMACOKINETICS; ATORVASTATIN; CLOPIDOGREL; METABOLISM;
D O I
10.1185/03007995.2012.747952
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 64 条
[21]   Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: Importance of interdisciplinary communication to prevent treatment errors with complex medications [J].
Geist, Marcus J. P. ;
Egerer, Gerlinde ;
Burhenne, Juergen ;
Riedel, Klaus-Dieter ;
Mikus, Gerd .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (09) :3455-3456
[22]   CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects [J].
Giessmann, T ;
Modess, C ;
Hecker, U ;
Zschiesche, M ;
Dazert, P ;
Kunert-Keil, C ;
Warzok, R ;
Engel, G ;
Weitschies, W ;
Cascorbi, I ;
Kroemer, HK ;
Siegmund, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) :213-222
[23]   Rifamycin treatment of tuberculosis in a patient receiving atenolol: Less interaction with rifabutin than with rifampin [J].
Goldberg, SV ;
Hanson, D ;
Peloquin, CA .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (04) :607-608
[24]   Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects A Single-Sequence, Open-Label Study [J].
Harrison, Brooke ;
Magee, Mindy H. ;
Mandagere, Arun ;
Walker, Gennyne ;
Dufton, Christopher ;
Henderson, Linda S. ;
Boinpally, Ramesh .
CLINICAL DRUG INVESTIGATION, 2010, 30 (12) :875-885
[25]   Rifampin and Posaconazole Coadministration Leads to Decreased Serum Posaconazole Concentrations [J].
Hohmann, Carina ;
Kang, Elizabeth M. ;
Jancel, Timothy .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (06) :939-940
[26]   Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel [J].
Judge, H. M. ;
Patil, S. B. ;
Buckland, R. J. ;
Jakubowski, J. A. ;
Storey, R. F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (08) :1820-1827
[27]   Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men [J].
Krishna, G. ;
Parsons, A. ;
Kantesaria, B. ;
Mant, T. .
CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (03) :545-552
[28]   Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects [J].
Kyrklund, C ;
Backman, JT ;
Neuvonen, M ;
Neuvonen, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :181-187
[29]   MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype [J].
Lamba, J ;
Strom, S ;
Venkataramanan, R ;
Thummel, KE ;
Lin, YS ;
Liu, W ;
Cheng, C ;
Lamba, V ;
Watkins, PB ;
Schuetz, E .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :325-338
[30]   Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J].
Lau, WC ;
Waskell, LA ;
Watkins, PB ;
Neer, CJ ;
Horowitz, K ;
Hopp, AS ;
Tait, AR ;
Carville, DGM ;
Guyer, KE ;
Bates, ER .
CIRCULATION, 2003, 107 (01) :32-37